参考文献/References:
[1] Leach MO,Brindle KM,Evelhoch JL,et al.The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging:issues and recommendations[J].Br J Cancer,2005,92(9):1599-1610.
[2] Patlak CS,Blasberg RG.Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data.Generalizations[J].J Cereb Blood Flow Metab,1985,5(4):584-590.
[3] Tofts PS,Kermode AG.Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging.1.Fundamental concepts[J].Magn Reson Med,1991,17(2):357-367.
[4] St Lawrence KS,Lee TY.An adiabatic approximation to the tissue homogeneity model for water exchange in the brain:I.Theoretical derivation[J].J Cereb Blood Flow Metab,1998,18(12):1365-1377.
[5] Tofts PS,Brix G,Buckley DL,et al.Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer:standardized quantities and symbols[J].J Magn Reson Imaging,1999,10(3):223-232.
[6] Leach MO,Morgan PS,Tofts PS,et al.Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging[J].Eur Radiol,2012,22(7):1451-1464.
[7] Tozer GM.Measuring tumor vascular response to antivascular and antiangiogenic drugs[J].Br J Radiol,2003,76(1):S23-35.
[8] Gregorc V,Citterio G,Vitali G,et al.Defining the optimal biological dose of NGR-hTNF,a selective vascular targeting agent,in advanced solid tumours[J].Eur J Cancer,2010,46(1):198-206.
[9] Murukesh N,Dive C,Jayson GC,et al.Biomarkers of angiogenesis and their role in the development of VEGF inhibitors[J].Br J Cancer,2010,102(1):8-18.
[10] Padhani AR.MRI for assessing antivascular cancer treatments[J].Br J Radiol,2003,76(1):S60-80.
[11] Yung WK,Friedman H,Conrad C,et al.A phase I trial of single-a-gent PTK 787/ZK 2225894(PTK/ZK),an oral VEGFR tyrosine kinase inhibitor,in patients with recurrent glioblastoma multiforme[C].Chicago:American Society of Clinical Oncology,2003:395.
[12] Cha S,Knopp EA,Johnson G,et al.Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin[J].AJNR Am J Neuroradiol,2000,21(5):881-890.
[13] Parker GJ,Suckling J,Tanner SF,et al.Probing tumor microvascularity by measurement,analysis and display of contrast agent uptake kinetics[J].J Magn Reson Imaging,1997,7(3):564-574.
[14] Anwar RP,Janet EH.Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification,validation and human studies[J].Clin Radiol,2001,56(8):607-620.
[15] Buckley DL,Drew PJ,Mussurakis S,et al.Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI[J].J Magn Reson Imaging,1997,7(3):461-464.
[16] Stomper PC,Winston JS,Herman S,et al.Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions[J].Breast Cancer Res Treat,1997,45(1):39-46.
[17] Knopp MV,Weiss E,Sinn HP,et al.Pathophysiologic basis of contrast enhancement in breast tumors[J].J Magn Reson Imaging,1999,10(3):260-266.
[18] O’Connor JP,Clamp AR,Carano RA,et al.Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor:insights from imaging[J].Clin Cancer Res,2009,15(21):6674-6682.
[19] Dowlati A,Robertson K,Cooney F,et al.A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4-phosphate on a single-dose intravenous schedule inpatients with advanced cancer[J].Cancer Res,2002,62(12):3408-3416.
[20] Galbraith SM,Rustin GJ,Lodge MA,et al.Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging[J].J Clin Oncol,2002,20(18):3826-3840.
[21] O’Cornor JP,Jackson A,Parker GJ,et al.Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies[J].NatRev Clin Oncol,2012,9(3):167-177.
[22] Evelhoch JL.Key factors in the acquisition of contrast kinetic data for oncology[J].J Magn Reson Imaging,1999,10(3):254-259.
[23] Thorpe PE.Vascular targeting agents as cancer therapeutics[J].Clin Cancer Res,2004,10(2):415-427.
[24] McPhail LD,Griffiths JR,Robinson SP.Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging[J].Int J Radiat Oncol Biol Phys,2007,69(4):1238-1245.
[25] Koh DM,Blackledge M,Collins DJ,et al.Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin-A4 phosphate and bevacizumab in a two-centre phase I clinical trial[J].Eur Radiol,2009,19(11):2728-2738.
[26] Galbraith SM,Maxwell RJ,Lodge MA,et al.Combretastatin-A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging[J].J Clin Oncol,2003,21(15):2831-2842.
[27] Gregorc V,Citterio G,Vitati G,et al.Defining the optimal biological dose of NGR-hTNF,a selective vascular targeting agent,in advanced solid tumours[J].Eur J Cancer,2010,46(1):198-206.
[28] Jonker DJ,Rosen LS,Sawyer MB,et al.A phase I study to determine the safety,pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor,brivanib,in patients with advanced or metastatic solid tumors[J].Ann Oncol,2011,22(6):1413-1419.
[29] Jackson A,O’Connor JP,Parker GJ,et al.Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging[J].Clin Cancer Res,2007,13(12):3449-3459.
[30] O’Connor JP,Jackson A,Parker GJ,et al.DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents[J].Br J Cancer,2007,96(2):189-195.
[31] Rehman S,Jayson GC.Molecular imaging of antiangiogenic agents[J].Oncologist,2005,10(2):92-103.
[32] Congress U.S.Food and drug administration modernization act of 1997[R].Virginia:U.S.FDA,1997:105-115.
[33] Hahn OM,Yang C,Medved M,et al.Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma[J].J Clin Oncol,2008,26(28):4572-4578.
[34] Dahut WL,Madan RA,Karakunnel JJ,et al.Phase Ⅱ clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer[J].BJU Int,2013,111(8):1269-1290.
[35] Kreisl TN,Zhang W,Odia Y,et al.A phase Ⅱ trial of single-agent bevacizumab in patients with recurrent anaplastic glioma[J].Neuro Oncol,2011,13(10):1143-1150.
[36] Lockhart AC,Rosenberg ML,Dupont J,et al.Phase I study of intravenous vascular endothelial growth factor trap,aflibercept,in patients with advanced solid tumors[J].J Clin Oncol,2010,28(2):207-214.
[37] Zhu AX,Sahani DV,Duda DG,et al.Efficacy,safety,and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma:a phase Ⅱ study[J].J Clin Oncol,2009,27(18):3027-3035.
[38] Liu G,Hope S,Wilding G,et al.Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736,an oral angiogenesis inhibitor,in patients with advanced solid tumors:results from a phase I study[J].J Clin Oncol,2005,23(24):5464-5473.
相似文献/References:
[1]岳进,苏丽萍.全身MRI与PET/CT在淋巴瘤骨髓浸润诊断及预后中的作用[J].国际放射医学核医学杂志,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
Yue Jin,Su Lipin.Function of whole-body MRI and PET/CT in the diagnosis and prognosis of lymphoma with bone marrow infiltration[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
[2]李敏,蒋涛,彭朋,等.直肠内注入模拟粪便的动态MRI对女性盆底痉挛综合征的诊断价值[J].国际放射医学核医学杂志,2016,40(3):165.[doi:10.3760/cma.j.issn.1673-4114.2016.03.001]
Li Min,Jiang Tao,Peng Peng,et al.Value of dynamic MRI with rectum injection in the diagnosis of female spastic pelvic floor syndrome[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):165.[doi:10.3760/cma.j.issn.1673-4114.2016.03.001]
[3]唐令胜,刘朝晖,李红梅,等.低场磁共振DWI技术与常规MRI扫描对超急性脑梗死的诊断灵敏度的比较[J].国际放射医学核医学杂志,2016,40(3):187.[doi:10.3760/cma.j.issn.1673-4114.2016.03.006]
Tang Lingsheng,Liu Zhaohui,Li Hongmei,et al.Comparison of the diagnostic sensitivity of low-field magnetic resonance diffusion weighted imaging technology and conventional MRI scanning for super acute cerebral infarction[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):187.[doi:10.3760/cma.j.issn.1673-4114.2016.03.006]
[4]贺小红,周新韩,高明勇,等.模型模拟修改部分扫描参数加速MR扫描的方法可行性探讨[J].国际放射医学核医学杂志,2016,40(4):267.[doi:10.3760/cma.j.issn.1673-4114.2016.04.006]
He Xiaohong,Zhou Xinhan,Gao Mingyong,et al.Feasibility of accelerating MR scan by modifying part of scanning parameters：a phantom simulation study[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):267.[doi:10.3760/cma.j.issn.1673-4114.2016.04.006]
[5]卢瑞梁,贺小红,蔡华清,等.不同MRI序列检出聚丙烯酰胺水凝胶注射隆乳患者乳腺病变效能的比较研究[J].国际放射医学核医学杂志,2016,40(6):435.[doi:10.3760/cma.j.issn.1673-4114.2016.06.007]
Lu Ruiliang,He Xiaohong,Cai Huaqing,et al.The different MRI sequences to detect breast lesions in polyacrylamide hydrogel injection for augmentation patients: a comparative study[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):435.[doi:10.3760/cma.j.issn.1673-4114.2016.06.007]
[6]廖光星,冷志欣,肖国有.前列腺癌骨转移影像诊断方法研究进展[J].国际放射医学核医学杂志,2016,40(6):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
Liao Guangxing,Leng Zhixin,Xiao Guoyou.Progress of imaging in the diagnosis of bone metastases of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
[7]马彦云,张辉.磁共振体素内不相干运动扩散加权成像的原理及应用进展[J].国际放射医学核医学杂志,2016,40(6):469.[doi:10.3760/cma.j.issn.1673-4114.2016.06.013]
Ma Yanyun,Zhang Hui.The basic principle and application progress of intravoxel incoherent motion imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):469.[doi:10.3760/cma.j.issn.1673-4114.2016.06.013]
[8]周金鑫,张一帆.胰岛细胞移植监测的分子影像学进展[J].国际放射医学核医学杂志,2015,39(6):478.[doi:10.3760/cma.j.issn.1673-4114.2015.06.009]
Zhou Jinxin,Zhang Yifan.Research progress of molecular imaging in monitoring islet transplantation[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):478.[doi:10.3760/cma.j.issn.1673-4114.2015.06.009]
[9]樊鹏,甄俊平,王峻.MR示踪技术在干细胞移植治疗软骨缺损中的研究进展[J].国际放射医学核医学杂志,2015,39(6):497.[doi:10.3760/cma.j.issn.1673-4114.2015.06.013]
Fan Peng,Zhen Junping,Wang Jun.The progress of magnetic resonance cell tracing technique in stem cells transplantation treatment of cartilage defects[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):497.[doi:10.3760/cma.j.issn.1673-4114.2015.06.013]
[10]张学花,翟昭华.胰腺微囊性腺瘤影像学报道一例[J].国际放射医学核医学杂志,2015,39(6):516.[doi:10.3760/cma.j.issn.1673-4114.2015.06.019]